Tokyo, Japan

Yusuke Ogitani

This inventor holds 13 USPTO granted patents and 4 published patent applications, plus 5 CIPO patents and 6 EPO patents, primarily in Antibody-Drug Conjugates. Top assignee: Daiichi Sankyo Company, Limited. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yusuke Ogitani. Retrieved from https://idiyas.com/inventor/yusuke-ogitani

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 13 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 8.7

ph-index = 6

Forward Citations = 113(Granted Patents)


Company Filing History:


Years Active: 2017-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Anti-HER2
Drug Resistance
Cancer Therapy
Antibody-Drug Conjugate
Tubulin Inhibitor
Hydrophilic Linker
Combination Therapy
Targeted Treatment
Cancer Treatment
Therapeutic Agents
Bioconjugates
Linker Design
13 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Yusuke Ogitani in Antitumor Drug Development

Introduction

Yusuke Ogitani, an accomplished inventor based in Tokyo, Japan, has made significant strides in the field of antitumor drug development. With a remarkable portfolio of 11 patents, Ogitani's work primarily focuses on creating antibody-drug conjugates that enhance the efficacy and safety of cancer treatments.

Latest Patents

Among Ogitani's latest patents, one noteworthy invention is an antibody-drug conjugate designed as an antitumor drug that excels in both antitumor effect and safety. This innovative conjugate links an antitumor compound to an antibody through a unique linker structure, facilitating targeted cancer therapy. Additionally, he has developed a method for treating cancer which employs the anti-HER2 antibody-drug conjugate, also showcasing superior antitumor effects and therapeutic efficacy. This conjugate effectively connects an antitumor compound to an anti-HER2 antibody, utilizing a specialized linker that enhances its therapeutic potential.

Career Highlights

Yusuke Ogitani currently holds a prominent position at Daiichi Sankyo Company, Limited, where he has contributed to groundbreaking research in pharmaceutical innovations. His extensive work in antibody-drug conjugates marks a pivotal contribution to cancer treatment methodologies, reflecting his dedication to improving patient outcomes through innovative drug design.

Collaborations

Throughout his career, Ogitani has collaborated with esteemed colleagues such as Hiroyuki Naito and Takashi Nakada. Together, they have advanced the field of oncology, emphasizing the importance of teamwork in the pursuit of scientific innovation and drug development.

Conclusion

Yusuke Ogitani stands out as a leading inventor in the field of antitumor drug development. His recent patents illustrate his commitment to advancing cancer treatment through innovative antibody-drug conjugates. With ongoing contributions and collaborations within Daiichi Sankyo Company, Limited, Ogitani’s work promises to influence the future of oncology and improve therapeutic strategies for cancer patients worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…